Simplex Trading
MRNA icon

Simplex Trading’s Moderna MRNA Stock Holding History

Simplex Trading’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$4.86M Sell
25,256
-129,302
-84% -$13.9M ﹤0.01% 1214
2026
Q2 		$10.8M Sell
154,558
-65,015
-30% -$3.36M 0.01% 710
2026
Q1 		$11.2M Buy
219,573
+129,897
+145% +$6.06M 0.01% 655
2025
Q4 		$2.64M Sell
89,676
-245,712
-73% -$6.68M ﹤0.01% 1756
2025
Q3 		$8.66M Sell
335,388
-46,399
-12% -$1.29M ﹤0.01% 1058
2025
Q2 		$10.5M Buy
381,787
+190,557
+100% +$5.02M 0.01% 858
2025
Q1 		$5.42M Buy
191,230
+87,027
+84% +$3.09M ﹤0.01% 1257
2024
Q4 		$4.33M Buy
+104,203
New +$4.98M ﹤0.01% 1588
2024
Q2 		– Sell
-24,885
Closed -$3.15M – 9432
2024
Q1 		$2.65M Buy
+24,885
New +$2.51M ﹤0.01% 2131
2023
Q4 		– Sell
-120,949
Closed -$10.2M – 9438
2023
Q3 		$12.5M Buy
120,949
+106,352
+729% +$11.9M 0.01% 821
2023
Q2 		$1.77M Buy
+14,597
New +$1.95M ﹤0.01% 2065
2022
Q4 		– Sell
-42,209
Closed -$6.9M – 9938
2022
Q3 		$4.99M Sell
42,209
-38,828
-48% -$5.89M 0.01% 1212
2022
Q2 		$11.6M Buy
81,037
+7,033
+10% +$1.01M 0.01% 742
2022
Q1 		$12.7M Buy
74,004
+72,754
+5,820% +$12.2M 0.01% 717
2021
Q4 		$317K Sell
1,250
-25,831
-95% -$7.55M ﹤0.01% 4479
2021
Q3 		$6.37M Sell
27,081
-3,694
-12% -$1.36M 0.01% 1011
2021
Q2 		$7.23M Buy
+30,775
New +$5.5M 0.01% 902
2021
Q1 		– Sell
-56,919
Closed -$8.25M – 9570
2020
Q4 		$5.95M Sell
56,919
-96,909
-63% -$9.8M 0.01% 862
2020
Q3 		$0 Buy
153,828
+40,423
+36% +$2.82M ﹤0.01% 8206
2020
Q2 		$7.28M Sell
113,405
-5,413
-5% -$296K 0.01% 654
2020
Q1 		$3.56M Buy
118,818
+86,366
+266% +$1.99M 0.01% 889
2019
Q4 		$634K Sell
32,452
-25,499
-44% -$452K ﹤0.01% 2514
2019
Q3 		$922K Buy
57,951
+10,813
+23% +$160K ﹤0.01% 2008
2019
Q2 		$690K Buy
47,138
+32,760
+228% +$704K ﹤0.01% 2273
2019
Q1 		$292K Buy
14,378
+13,278
+1,207% +$246K ﹤0.01% 3220
2018
Q4 		$16K Buy
+1,100
New +$18.1K ﹤0.01% 5521

Other funds holding MRNA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $106B AUM 2.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Banque Pictet & Cie
Banque Pictet & Cie Geneva 73, Switzerland $14.5B AUM 33.71% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Douglas Lane & Associates
Douglas Lane & Associates New York $7.46B AUM 24.36% 1-Year Est. Return
Beau Ventures
Beau Ventures Pittsford, New York $1.06B AUM 83.06% 1-Year Est. Return

Simplex Trading's MRNA Position: Q3 2026 in Review

Simplex Trading reduced its Moderna (MRNA) stake by 84% in Q3 2026, selling an estimated $13.9M and leaving 25,256 shares worth $4.86M. The position accounts for ﹤0.01% of the portfolio, ranked #1214.

Simplex Trading first reported a position in MRNA in Q4 2018 and has held it in 26 quarters since. The position peaked at $12.7M in Q1 2022. 633 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • Simplex Trading held 25,256 shares of Moderna worth $4.86M as of Q3 2026.
  • Simplex Trading sold 129,302 Moderna shares in Q3 2026, an estimated $13.9M.
  • Moderna made up ﹤0.01% of Simplex Trading's portfolio in Q3 2026, its #1214 holding.
  • Simplex Trading first reported a position in Moderna in Q4 2018 and has held it in 26 quarters since.
  • Simplex Trading's Moderna position peaked at $12.7M in Q1 2022.
  • 633 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on Simplex Trading's 13F filing for Q3 2026, filed 4 Nov 2026.